GLP-1RA对糖尿病心肌病的保护机制研究进展  

Research of Glucagon-like peptide-1 receptor agonists in cardioprotective mechanism

作　　者：索斯琪 高宇[1] 刘晓燕[1] SUO Siqi;GAO Yu;LIU Xiaoyan(Department of Endocrinology,Affiliated Hospital of Chengde Medical University,Chengde,Hebei 067000,China)

机构地区：[1]承德医学院附属医院内分泌科,河北省承德市067000

出　　处：《中国动脉硬化杂志》2025年第3期264-268,276,共6页Chinese Journal of Arteriosclerosis

基　　金：河北省自然科学基金项目(C2022406011);承德市科技局基础研究项目(202205B074)。

摘　　要：2型糖尿病(T2DM)是一种常见的慢性代谢性疾病,与非糖尿病相比,T2DM患者患心脏疾病的风险更高,其患血管疾病的风险是非糖尿病患者的两倍。多项临床试验证实,胰高血糖素样肽1受体激动剂(GLP-1RA)除了具有降低血糖的功能外,还可以降低T2DM患者发生心血管事件的风险。本文就近年来GLP-1RA介导的心脏保护机制的进展作一综述,阐述GLP-1RA对心脏特定细胞的保护机制,进一步探讨其对心力衰竭(HF)的影响,为临床治疗糖尿病心肌病提供帮助。Diabetes mellitus type 2(T2DM)is a common chronic metabolic disease,compared to non-diabetics,T2DM patients have a higher risk of heart disease,and their risk of vascular diseases is twice that of non-diabetic individuals.Multiple clinical trials have confirmed that glucagon-like peptide-1 receptor agonists(GLP-1RA),in addition to their function of lowering blood glucose,can also decrease the risk of cardiovascular events in T2DM patients.This article reviews the mechanisms of GLP-1RA-mediated cardioprotection.It provides a comprehensive review of the recent progress in GLP-1RA-mediated cardiac protective mechanisms,elaborating on the protective effects of GLP-1RA on specific heart cell and further discussing its impact on heart failure(HF),provide assistance for clinical treatment of diabetic cardiomyopathy.

关 键 词：胰高血糖素样肽1受体激动剂 糖尿病心肌病 心力衰竭 

分 类 号：R5[医药卫生—内科学]